Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Bayer puts part of Roundup settlement on hold

Published 07/08/2020, 09:51 AM
Updated 07/08/2020, 10:25 AM
© Reuters. FILE PHOTO: Logo of Bayer AG at a plant of the German pharmaceutical and chemical maker in Wuppertal

FRANKFURT (Reuters) - Bayer (DE:BAYGn) has agreed to delay part of a proposed settlement of allegations that its widely used weedkiller Roundup caused cancer after a U.S. judge questioned its plan to deal with future claims.

The German company said on Wednesday that lawyers representing those preparing a class action had withdrawn a request for court approval of the $1.25 billion scheme, part of a broader $10.9 billion agreement to settle close to 100,000 U.S. lawsuits related to Roundup.

The move would give the parties more time to address questions raised by Federal District Court Judge Vince Chhabria of the Northern District of California who presides over the federal Roundup litigation, Bayer said in a statement.

"Bayer remains strongly committed to a resolution that simultaneously addresses both the current litigation on reasonable terms and a viable solution to manage and resolve potential future litigation", it added.

It declined to comment on the impact of the withdrawal on the timetable for the rest of the settlement.

Bayer is seeking to end legal disputes it inherited with its $63 billion takeover of Monsanto (NYSE:MON) in 2018.

Bayer shares were down 1.2% by 1307 GMT.

On Tuesday, Bayer (De:BAYGn) shares had fallen more than 6% after Chhabria said that the court was inclined to oppose the part of the proposed settlement that deals with future claims. The case was due to be considered again on July 24.

Bayer had planned to create an independent panel of scientific experts to help assess whether glyphosate caused cancer.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

But in a filing published on July 6, Chhabria had questioned the idea of delegating the decision from judges and juries to a panel of scientists.

Chhabria also questioned whether potential claimants would want to remain bound by a ruling reached by the proposed scientific panel if research is still ongoing.

Regulators including the U.S. Environmental Protection Agency and the European Chemicals Agency, have determined glyphosate to be non-carcinogenic, supporting Bayer's claim that the active ingredient in its Roundup product is safe for agricultural use.

However, in 2015, the World Health Organization's cancer research arm determined the herbicide to be a "probable carcinogen", and since 2018, three consecutive U.S. juries, who listened to scientific evidence from both sides during trials, found that Roundup causes cancer. (This story is refiled to fix day in second paragraph)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.